Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B
JACC: Advances
Transthyretin Amyloidosis (ATTR)
Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis
Molecular Therapy Nucleic Acids
Cardiovascular (CV)
Add-on Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial
Journal of the American Medical Association
Transthyretin Amyloidosis (ATTR)
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: A plain language summary
Future Cardiology
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial
American Journal of Kidney Diseases
Transthyretin Amyloidosis (ATTR)
Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study
Orphanet Journal of Rare Diseases
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis with Cardiomyopathy
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy
Journal of the American College of Cardiology
